APP and familial Alzheimer disease: By screening exon 17 of APP and the coding exons of PS1 and PS2, a mutation detection rate of ~57% [7] can be achieved in patients with suspected familial AD (FAD), a figure comparable to those of earlier reports (46–71%) [8-10].